EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease

Rajeev Kumar, Pinky Agarwal, Karen Anderson, Daniel Claassen, Marissa Dean, Andrew Duker, Burton Scott, Benjamin Hoehn, Ann Mongan, Ping Lin, Ellen Cahir-McFarland, Lori Taylor und 4 weitere

Movement Disorders · 2026-06 · 41 (6) · 1492-1501

DOI: 10.1002/mds.70229 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Movement Disorders, online erschienen am 05.03.2026. Verfasst von Rajeev Kumar und 15 weiteren Autor:innen. Beteiligte Einrichtung: Rocky Mountain Movement Disorders Center, Englewood, Colorado, USA. Hauptthemen laut MEDLINE: Huntington Disease, Antibodies, Monoclonal, Humanized, Complement C1q. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Annexon Biosciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The classical complement pathway is implicated in the progression of neurodegenerative disease through its ability to drive aberrant removal of synapses, neuroinflammation, and neuronal damage. ANX005 is a humanized monoclonal antibody targeting C1q that blocks classical complement pathway activation.

Objective

The aim was to assess the safety, pharmacokinetics (PK), pharmacodynamics, and clinical activity of ANX005 in patients with Huntington's disease (HD).

Methods

ANX005‐HD‐01 (NCT04514367) was a multicenter, open‐label, phase 1b study in patients with early‐manifest HD. Primary endpoints included safety, tolerability, PK, and complement C1q and C4a/C4 levels in the serum and cerebrospinal fluid (CSF). Exploratory clinical activity endpoints included changes from baseline in composite Unified Huntington's Disease Rating Scale (cUHDRS) and component scores.

Results

All patients who received study drug (n = 28) experienced ≥1 treatment‐emergent adverse event, mostly transient infusion‐related reactions on the first dose. Three patients with elevated baseline antinuclear antibodies withdrew from the study due to treatment‐related AEs (pneumonitis) or serious AEs (systemic lupus erythematous, hemolysis). Twenty‐three patients (82.1%) received all planned ANX005 infusions. Steady‐state PK was achieved by week 6, with full saturation of ANX005 observed in serum and the CSF. Stabilization or possible improvement in cUHDRS and total functional capacity through 36 weeks was observed in a patient subgroup with higher baseline complement activity, based on baseline C4a/C4 ratio in CSF.

Conclusion

Overall, AEs with ANX005 administration were manageable, and most patients received all planned doses. Evidence of clinical improvement with ANX005 was observed in patients with higher baseline complement activity, supporting future study in patients with HD. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseAntibodies, Monoclonal, HumanizedComplement C1qHumansFemaleMaleAdultMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

ANX005C1qHuntington's diseaseclassical complement cascadeclinical trial

Substanzen

Antibodies, Monoclonal, HumanizedComplement C1q

Autor:innen und Institutionen

  • Rocky Mountain Movement Disorders Center, Englewood, Colorado, USA.
  • Evergreen Healthcare, Kirkland, Washington, USA.
  • Georgetown University, Washington, DC, USA.
  • Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • UC Gardner Neuroscience Institute, Cincinnati, Ohio, USA.

Förderung

  • Annexon Biosciences

Zitieren

APA

Kumar, R., Agarwal, P., Anderson, K., Claassen, D., Dean, M., Duker, A., Scott, B., Hoehn, B., Mongan, A., Lin, P., Cahir-McFarland, E., Taylor, L., Morrison, G., Yednock, T., Keswani, S., & Kroon, H. A. (2026). An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease. Movement Disorders, 41(6), 1492-1501. https://doi.org/10.1002/mds.70229

Vancouver

Kumar R, Agarwal P, Anderson K, Claassen D, Dean M, Duker A, et al. An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease. Movement Disorders. 2026;41(6):1492-1501. doi:10.1002/mds.70229

BibTeX
@article{Kumar2026,
  author = {Kumar, Rajeev and Agarwal, Pinky and Anderson, Karen and Claassen, Daniel and Dean, Marissa and Duker, Andrew and Scott, Burton and Hoehn, Benjamin and Mongan, Ann and Lin, Ping and Cahir-McFarland, Ellen and Taylor, Lori and Morrison, Glenn and Yednock, Ted and Keswani, Sanjay and Kroon, Henk-Andre},
  title = {An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease},
  journal = {Movement Disorders},
  year = {2026},
  volume = {41},
  number = {6},
  pages = {1492--1501},
  doi = {10.1002/mds.70229}
}
Kostenlos starten →